IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+14.89%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$283M
AUM Growth
+$283M
(+18%)
Cap. Flow
+$47.2M
Cap. Flow
% of AUM
16.65%
Top 10 Holdings %
Top 10 Hldgs %
54.99%
Holding
128
New
25
Increased
11
Reduced
19
Closed
34
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$61M |
| 2 |
IDEAYA Biosciences
IDYA
|
$11.5M |
| 3 |
Nuvalent
NUVL
|
$11.5M |
| 4 |
Disc Medicine
IRON
|
$10.7M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$8.56M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1
DELISTED
ACELYRIN
SLRN
| $61M | 9.71% | +2,918,426 | New | +$61M |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $12.2M | 1.94% | 133,800 +33,800 | +34% | +$3.08M |
|
3
Merck
MRK
$210B
| $11.5M | 1.84% | 100,000 | – | – |
|
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $11.5M | 1.84% | +490,893 | New | +$11.5M |
|
|
5
Nuvalent
NUVL
$5.52B
| $11.5M | 1.83% | +272,752 | New | +$11.5M |
|
|
6
Disc Medicine
IRON
$2.07B
| $10.7M | 1.7% | +240,031 | New | +$10.7M |
|
7
Insmed
INSM
$28.8B
| $10.2M | 1.63% | 485,000 | – | – |
|
8
Biohaven
BHVN
$1.63B
| $10.2M | 1.63% | 427,417 +25,091 | +6% | +$600K |
|
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.56M | 1.36% | +475,000 | New | +$8.56M |
|
|
IMGN
10
DELISTED
Immunogen Inc
IMGN
| $8.45M | 1.35% | +447,700 | New | +$8.45M |
|
11
BridgeBio Pharma
BBIO
$9.89B
| $7.39M | 1.18% | 429,686 -165,000 | -28% | -$2.84M |
|
12
Vaxcyte
PCVX
$4B
| $6.99M | 1.11% | 140,000 -85,000 | -38% | -$4.24M |
|
|
MRNS
13
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.65M | 1.06% | +611,932 | New | +$6.65M |
|
14
Biomea Fusion
BMEA
$116M
| $6.06M | 0.96% | 275,875 +64,900 | +31% | +$1.42M |
|
15
Arcus Biosciences
RCUS
$1.13B
| $5.69M | 0.91% | 280,000 +50,000 | +22% | +$1.02M |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $5.61M | 0.89% | +121,658 | New | +$5.61M |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $5.22M | 0.83% | 135,486 -25,000 | -16% | -$963K |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| $5.18M | 0.83% | 203,037 -4,075 | -2% | -$104K |
|
19
Astria Therapeutics
ATXS
$349M
| $4.83M | 0.77% | 579,390 -290,000 | -33% | -$2.42M |
|
20
Arrowhead Research
ARWR
$3.05B
| $4.64M | 0.74% | +130,000 | New | +$4.64M |
|
21
Lyra Therapeutics
LYRA
$11.5M
| $4.02M | 0.64% | 978,626 +634,941 | +185% | +$2.61M |
|
|
LBPH
22
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $3.7M | 0.59% | +504,253 | New | +$3.7M |
|
23
Voyager Therapeutics
VYGR
$186M
| $3.44M | 0.55% | +300,000 | New | +$3.44M |
|
|
ALLK
24
DELISTED
Allakos
ALLK
| $3.37M | 0.54% | +772,092 | New | +$3.37M |
|
25
Acumen Pharmaceuticals
ABOS
$82.4M
| $3.15M | 0.5% | 654,945 +400,000 | +157% | +$1.92M |
|